Peptides displayed by HLA for use in immunotherapy against different types of cancers

Patent metadata

Field	Value
Publication number	US-12246039-B2
Application number	US-202418585158-A
Country	US
Kind code	B2
Filing date	Feb 23, 2024
Priority date	Jan 15, 2021
Publication date	Mar 11, 2025
Grant date	Mar 11, 2025

Abstract

The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

First claim

What is claimed is:

1. A peptide consisting of the amino acid sequence AYIPFPPLI (SEQ ID NO: 33) in the form of a pharmaceutically acceptable salt.

2. The peptide of claim 1 , wherein the pharmaceutically acceptable salt is chloride salt.

3. The peptide of claim 1 , wherein the pharmaceutically acceptable salt is acetate salt.

4. A composition comprising the peptide of claim 1 and a pharmaceutically acceptable carrier.

5. The composition of claim 4 , wherein the peptide is in the form of a chloride salt.

6. The composition of claim 4 , wherein the peptide is in the form of an acetate salt.

7. The composition of claim 4 , further comprising an adjuvant selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I: C) and derivatives, RNA, sildenafil, particulate formulations with poly (lactide co-glycolide) (PLG), virosomes, and cytokines comprising eotaxin, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon (INF)-γ, interleukin (IL)-1α, macrophage colony-stimulating factor (M-CSF), IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12p40, IL-13, IL-18, IL-15, IL-17, interferon γ-induced protein 10 kDa (IP-10), macrophage inflammatory protein (MIP)-2, keratinocyte chemoattractant (KC), leukemia inhibitory factor (LIF), lipopolysaccharide-induced CXC chemokine (LIX), monocyte chemoattractant protein-1 (MCP-1), MIP-1α, MIP-1β, monokine induced by interferon-gamma (MIG), RANTES, tumor necrosis factor (TNF)-α, IL-12p70, vascular endothelial growth factor (VEGF), IL-9, and IL-21.

8. The composition of claim 7 , wherein the adjuvant is IL-2.

9. The composition of claim 7 , wherein the adjuvant is IL-15.

10. A pegylated peptide consisting of the amino acid sequence of AYIPFPPLI (SEQ ID NO: 33) or a pharmaceutically acceptable salt thereof modified with PEG.

11. The pegylated peptide of claim 10 , wherein the pharmaceutically acceptable salt is chloride salt.

12. The pegylated peptide of claim 10 , wherein the pharmaceutically acceptable salt is acetate salt.

13. A peptide consisting of the amino acid sequence AYIPFPPLI (SEQ ID NO: 33) in the form of a salt.

14. A method of treating a patient who has cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence of AYIPFPPLI (SEQ ID NO: 33), wherein the cancer is selected from the group consisting of acute myeloid leukemia, breast cancer, cholangiocellular carcinoma, chronic lymphocytic leukemia, colorectal cancer, gallbladder cancer, glioblastoma, gastric cancer, gastro-esophageal junction cancer, hepatocellular carcinoma, head and neck squamous cell carcinoma, melanoma, non-Hodgkin lymphoma, non-small cell lung cancer, ovarian cancer, esophageal cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, small cell lung cancer, urinary bladder carcinoma, and uterine endometrial cancer.

15. The method of claim 14 , wherein the T cells are transduced with a T cell receptor (TCR) that binds the peptide in a complex with an MHC class I molecule on the surface of the cancer cells.

16. The method of claim 14 , wherein the cancer is hepatocellular carcinoma.

17. The method of claim 14 , wherein the cancer is prostate cancer.

18. The method of claim 14 , further comprising administering to said patient an adjuvant selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I: C) and derivatives, RNA, sildenafil, particulate formulations with poly (lactide co-glycolide) (PLG), virosomes, and cytokines comprising eotaxin, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon (INF)-γ, interleukin (IL)-1α, macrophage colony-stimulating factor (M-CSF), IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12p40, IL-13, IL-18, IL-15, IL-17, interferon γ-induced protein 10 kDa (IP-10), macrophage inflammatory protein (MIP)-2, keratinocyte chemoattractant (KC), leukemia inhibitory factor (LIF), lipopolysaccharide-induced CXC chemokine (LIX), monocyte chemoattractant protein-1 (MCP-1), MIP-1α, MIP-1β, monokine induced by interferon-gamma (MIG), RANTES, tumor necrosis factor (TNF)-α, IL-12p70, vascular endothelial growth factor (VEGF), IL-9, and IL-21.

19. The method of claim 18 , wherein the adjuvant is IL-2.

20. The method of claim 18 , wherein the adjuvant is IL-15.

Assignees

• Immatics Biotechnologies Gmbh

Inventors

• Hannen Ricarda
• Hukelmann Jens
• Koehler Florian
• Kowalewski Daniel Johannes
• Schuster Heiko
• Schoor Oliver
• Roemer Michael
• Tsou Chih-Chiang
• Fritsche Jens

Classifications

• A61K40/42

  Cancer antigens · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• C12N5/0636

  T lymphocytes · CPC title

• C07K14/4748 Primary

  Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE · CPC title

• A61K39/0011 Primary

  Cancer antigens · CPC title